FUNDING
None of our work would be possible without the support we receive from our generous funders past and present. Currently, our work receives funding from:
Worldwide Cancer Research (WWCR)
Microenvironmental containment of tumours through paracrine
secretion (2023-2025)
We discovered that mammary gland adipocytes secrete a potent
anti-invasive cue, insulin-like growth factor binding protein 2
(IGFBP2), which efficiently blocks triple-negative breast cancer
cell invasion in vitro and in vivo. In this project, we aim to
uncover the molecular pathways underpinning IGFBP2 anti-invasive
activity in the mammary gland.
Jane Ja Aatos Erkon Säätiö
Cancer metastasis – new biological paradigms as drug targets (2023 –
2027)
In this project, we aim to explore the mechanisms of cancer-cell
intravasation and extravasation.
Juseslius Foundation
Scaffolding Oncogenic Signaling – identification of clinically
relevant signaling integrators (2023-2026)
Recently, we uncovered a scaffolding protein as a key regulator of
oncogenic KRAS signaling in PDAC with important clinical
implications. Now, we aim to gain a deeper understanding of its
function in NSCLC and CRC and assess its role beyond KRAS.
The Academy of Finland
BarrierForce Centre of Excellence - Biological Barrier Mechanics and
Disease: From molecular-scale to tissue-level understanding of
signal integration and forces (2022-2029)
Research Project - Adhesion dynamics and mechanobiological pathways
as determinants of oncogenic properties (2019-2023)
Cancer Society of Finland
Receptor sorting and cytoskeletal regulation in breast cancer (2020-2023)
Other partners
The Finnish Cancer Institute
The European Research Council
European Molecular Biology Organization
